Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms

NCT ID: NCT05626504

Last Updated: 2024-03-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-27

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this project the investigators study the safety and efficacy of the pipeline embolization device with vantage technology in treatment of unruptured brain aneurysms

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Aneurysm Intracranial Hemorrhages Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pipeline Embolization Device with Vantage Technology

Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients treated with Pipeline Embolization Device with Vantage Technology (PEDV)
* MRA and/or DSA (or tomographic angiography) available for follow up

Exclusion Criteria

* Insufficient background data available e.g., to determine size of aneurysm and pipeline device
* PEDV used for causes other than aneurysms, e.g., fistulas and dissection.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King's College Hospital NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kings College Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Atasoy D, Kandasamy N, Hart J, Lynch J, Yang SH, Walsh D, Tolias C, Booth TC. Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU). AJNR Am J Neuroradiol. 2019 Dec;40(12):2094-2101. doi: 10.3174/ajnr.A6314. Epub 2019 Nov 14.

Reference Type BACKGROUND
PMID: 31727754 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

317314

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Medical Device to Treat Wide-Neck Brain Aneurysms
NCT05550571 ACTIVE_NOT_RECRUITING NA
Global Fenestrated Anaconda Clinical STudy
NCT03180996 ACTIVE_NOT_RECRUITING
Barrow Ruptured Aneurysm Trial
NCT01593267 UNKNOWN NA